BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
IC50&Target
PD1-PDL1
体外研究
Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy.
Cell Cytotoxicity Assay
Cell Line:
NK cells and HepG2 cells
Concentration:
1 μM
Incubation Time:
3 days
Result:
Disturbed the interaction between PD-1 and PD-L1.
体内研究
BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.
Animal Model:
BALB/c mice with EMT6 cells
Dosage:
500 μg/mL; 100 μL
Administration:
I.p.
Result:
Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group.
mVEGF165b combined with MUC1 results significant retardation of the tumor growth.
分子式
C29H33NO5
分子量
475.58
CAS号
1675201-83-8
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
溶解性数据
In Vitro:
DMSO : 25 mg/mL (52.57 mM; ultrasonic and warming and heat to 60°C)